Skip to main content
SpringerLink
Log in

Protocoles à base de gemcitabine et taxanes dans le cancer du sein

  • Review Article
  • Published:
American Journal of Cancer

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Références

  1. Fountzilas G, Nicolaides C, Bafaloukos D, et al. Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group phase II study. Cancer Invest 2000; 18: 503–9

    Article  PubMed  CAS  Google Scholar 

  2. Lenz F, Schneeweiss A, Beldermann F, et al. 2002. A phase II study or first-line combination chemotherapy with docetaxel and gemcitabine in anthracycline-pretreated, Her2-negative, metastatic breast cancer. Ann Oncol 2001; 13 (suppl 5): [abstract 188P]

  3. Mavroudis D, Malamos N, Alexopoulos A, et al. 1999. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Ann Oncol 1999; 10: 211–5

    Article  PubMed  CAS  Google Scholar 

  4. Laufman LR, Spiridonidis CH, Pritchard J, et al. Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial. Ann Oncol 2001; 12: 1259–64

    Article  PubMed  CAS  Google Scholar 

  5. Komek GV, Haider K, Kwasny W, et al. Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor. Clin Cancer Res 2002; 8: 1051–6

    Google Scholar 

  6. Garle PA, Calvo L, Mayordomo JI, et al. Gemcitabine and docetaxel given every other week as first-line therapy for metastatic breast cancer (MBC): final results of a phase II study conducted within the Breast Cancer Investigation Spanish Group (GEICAM). Proc ASCO 2003; 22: [abstract 201]

  7. Colomer R, Llombart A, Lluch A, et al. Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial. Semin Oncol 2000; 27: 20–4

    PubMed  CAS  Google Scholar 

  8. Sanchez-Rovira P, Gonzalez E, Medina MB, et al. Results from a phase II study of gemcitabine in combination with paclitaxel in metastatic breast cancer. Breast Cancer Res Treatment 1999; 57: [abstract 344]

  9. Vici P, Foggi P, Capomolla E, et al. 2002. Biweekly paclitaxel/gemcitabine as salvage treatment in breast cancer patients: preliminary results. Proc ASCO 2002; 21 (part 2): 61b [abstract 2054]

    Google Scholar 

  10. Delfino C, Caccia GM, Gonzales LR, et al. Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer. Oncology 2004; 66: 18–23

    Article  PubMed  CAS  Google Scholar 

  11. Genot JY, Tubiana-Hulin M, Tubiana-Hulin N, et al. Gemcitabine and paclitaxel in metastatic breast cancer: a phase II study in first line setting. Proc Am Soc Clin Oncol 2002; [abstract 2002]

  12. Murad AM, Guimaraes RC, Aragao BC, et al. Phase II trial of the use of paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer. Am J Clin Oncol 2001; 24: 264–8

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut Catala d’Oncologia, Hospital Dr Josep Trueta, 17007, Girona, Espagne

    Ramon Colomer

Authors
  1. Ramon Colomer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ramon Colomer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Colomer, R. Protocoles à base de gemcitabine et taxanes dans le cancer du sein. Am J Cancer 3 (Suppl 2), 19–20 (2004). https://doi.org/10.2165/00024669-200403992-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024669-200403992-00009

Search

Navigation